Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer
NCT03666442
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
61
Enrollment
OTHER
Sponsor class
Conditions
Rectal Cancer
Interventions
DRUG:
XELOX
Sponsor
West China Hospital